GGrantIndex
← Leaderboards

Azizul Haque

Ralph H Johnson Va Medical Center

$1,697,171
Attributed
$1,902,733
Total exposure
4
Grants
3
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $411.1K · FY200925
$500K$375K$250K$125K$0
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$1,902,733 · 2
VA$0 · 2

By mechanism

R01$1,491,608 · 1
R21$411,125 · 1
I01$0 · 2

Top collaborators

Others in their field

Top investigators on “Cd4 Positive T Lymphocytes

Research focus

Cd4 Positive T LymphocytesT-LymphocyteCellsCd8b1 GeneProteinsProductionAffectSamplingKnock-DownAntigen PresentationPlayFlow CytometryIn VitroMediatingLeukemia/LymphomaMaintenanceCytotoxic T-LymphocytesMalignant Lymphoid NeoplasmB-Cell NeoplasmImmune ResponseB-Cell LymphomasCd8-Positive T-LymphocytesImmuneImmunologic Surveillance

Grant awards (14)

A Novel Mechanism of Immune Escape by B-cell Lymphoma$0
I01 · FY2025 · VA · contact PI
A Novel Mechanism of Immune Escape by B-cell Lymphoma$0
I01 · FY2024 · VA · contact PI
Attenuation of Inflammatory Response in Progressive Neurodegeneration in Parkinson's Disease$0
I01 · FY2023 · VA
Attenuation of Inflammatory Response in Progressive Neurodegeneration in Parkinson's Disease$0
I01 · FY2022 · VA
Attenuation of Inflammatory Response in Progressive Neurodegeneration in Parkinson's Disease$0
I01 · FY2021 · VA
Calpain cleavage of α-synuclein and T-cell reactivity in Parkinson’s disease$411,125
R21 · FY2020 · NS · contact PI
Attenuation of Inflammatory Response in Progressive Neurodegeneration in Parkinson's Disease$0
I01 · FY2020 · VA
Attenuation of Inflammatory Response in Progressive Neurodegeneration in Parkinson's Disease$0
I01 · FY2019 · VA
Disruption of HLA Class II-Mediated Immune Recognition of B-Cell Lymphomas$279,069
R01 · FY2013 · CA · contact PI
Disruption of HLA Class II-Mediated Immune Recognition of B-Cell Lymphomas$296,881
R01 · FY2012 · CA · contact PI
Disruption of HLA Class II-Mediated Immune Recognition of B-Cell Lymphomas$296,881
R01 · FY2011 · CA · contact PI
Disruption of HLA Class II-Mediated Immune Recognition of B-Cell Lymphomas$303,106
R01 · FY2010 · CA · contact PI
Disruption of HLA Class II-Mediated Immune Recognition of B-Cell Lymphomas$300,543
R01 · FY2009 · CA · contact PI
Disruption of HLA Class II-Mediated Immune Recognition of B-Cell Lymphomas$15,128
R01 · FY2009 · CA · contact PI